Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | TDO2 | P48775 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17069283 | 0.86 | IDO1 (0.47) | IDO1TDO2CES2CES1GAA | |
| SCHEMBL17069280 | 0.86 | IDO1 (0.47) | IDO1TDO2CES2CES1GAA | |
| SCHEMBL684363 | 0.86 | IDO1 (0.47) | IDO1TDO2CES2CES1GAA | |
| SCHEMBL21910183 | 0.79 | TAAR1 (0.36) | IDO1TDO2TAAR1SLC6A2SLC6A4 | |
| SCHEMBL21910181 | 0.76 | ALDH1A1 (0.39) | IDO1TDO2GAASLC6A2SLC6A4 | |
| SCHEMBL23085221 | 0.74 | CES2 (0.43) | CES2CES1SLC6A2MEN1KMT2A | |
| SCHEMBL23126407 | 0.73 | FFAR1 (0.41) | IDO1TDO2CES2CES1GAA | |
| SCHEMBL420964 | 0.73 | GABRA1 (0.48) | CES2CES1SLC6A2MEN1KMT2A | |
| SCHEMBL21831230 | 0.73 | CES2 (0.47) | IDO1TDO2CES2CES1GAA | |
| SCHEMBL30910879 | 0.73 | CES2 (0.47) | IDO1TDO2CES2CES1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | IDO1 1773/4885TDO2 3317/4885CES2 4302/4885 |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | IDO1 1773/4885TDO2 3317/4885CES2 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.